Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Other: TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Drug: Nivolumab

First Posted Date: 2018-03-23

Last Posted Date: 2024-02-13

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 18

Registration Number: NCT03475134

Locations: 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma
Non-Hodgkin Lymphoma

Interventions: Drug: Glofitamab
Drug: Obinutuzumab (G)
Drug: Rituximab (R)
Drug: Tocilizumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Polatuzumab vedotin
Drug: Prednisone

First Posted Date: 2018-03-16

Last Posted Date: 2024-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 172

Registration Number: NCT03467373

Locations: 🇩🇰
Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
🇺🇸
University of Alabama Medical Center, Birmingham, Alabama, United States
🇺🇸
Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States

and more 21 locations

Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tacrolimus
Radiation: Total Marrow Irradiation

First Posted Date: 2018-03-16

Last Posted Date: 2024-02-16

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 18

Registration Number: NCT03467386

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Phase 1

Active, not recruiting

Conditions: Acute Lymphocytic Leukemia, Pediatric
B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tocilizumab
Drug: Cytarabine
Drug: Etoposide
Drug: Dexamethasone

First Posted Date: 2018-03-15

Last Posted Date: 2023-02-24

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 18

Registration Number: NCT03467256

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Phase 1

Completed

Conditions: HLA-A*0201 Positive Cells Present
NY-ESO-1 Positive Tumor Cells Present
Recurrent Synovial Sarcoma
Recurrent Myxoid Liposarcoma

Interventions: Biological: Aldesleukin
Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Drug: Cyclophosphamide
Biological: Dendritic Cell-targeting Lentiviral Vector ID-LV305

First Posted Date: 2018-03-01

Last Posted Date: 2023-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT03450122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-08
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-02-28

Last Posted Date: 2024-07-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 32

Registration Number: NCT03448978

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Virgina Cancer Specialists, Fairfax, Virginia, United States

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Ovarian Carcinosarcoma
Poorly Differentiated Thyroid Gland Carcinoma
Platinum-Resistant Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Triple Negative Breast Cancer
Bone Sarcoma
Malignancy in Giant Cell Tumor of Bone
Thyroid Gland Anaplastic Carcinoma
Refractory Osteosarcoma
Dedifferentiated Chondrosarcoma

Interventions: Biological: Aldesleukin
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Drug: Cyclophosphamide
Other: Quality-of-Life Assessment
Drug: Fludarabine
Biological: Ipilimumab
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2018-02-28

Last Posted Date: 2024-11-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03449108

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1

Recruiting

Conditions: B-Cell Lymphoma
Acute Lymphocytic Leukemia
B-Cell Leukemia
B-Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, B Cell
Acute Lymphoid Leukemia
B-NHL
Acute Lymphoblastic Leukemia
B-All

Interventions: Biological: CD19/CD22 CAR T-Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-02-28

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT03448393

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2018-02-22

Last Posted Date: 2021-03-10

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 9

Registration Number: NCT03440411

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CAR-T Cells

First Posted Date: 2018-02-15

Last Posted Date: 2025-01-06

Lead Sponsor: Benjamin Tomlinson

Target Recruit Count: 31

Registration Number: NCT03434769

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy